|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0003364,
umls-concept:C0004147,
umls-concept:C0017431,
umls-concept:C0149721,
umls-concept:C0288171,
umls-concept:C0392747,
umls-concept:C0443172,
umls-concept:C0455825,
umls-concept:C1261322,
umls-concept:C1704256,
umls-concept:C1710263
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2004-3-30
|
|
pubmed:abstractText |
Angiotensin II, via the angiotensin II type 1 (AT1) receptor, may mediate myocardial fibrosis and myocyte hypertrophy seen in hypertensive left ventricular (LV) hypertrophy through production of transforming growth factor beta1 (TGF-beta1); AT1-receptor antagonists reverse these changes. The TGF-beta1 G + 915C polymorphism is associated with interindividual variation in TGF-beta1 production. No study has yet determined the impact of this polymorphism on the response to antihypertensive treatment.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
0160-9289
|
|
pubmed:author |
pubmed-author:BillbergerKatarinaK,
pubmed-author:FanP FPF,
pubmed-author:HallbergPärP,
pubmed-author:KahanThomasT,
pubmed-author:KarlssonJuliaJ,
pubmed-author:KurlandLisaL,
pubmed-author:LiljedahlUlrikaU,
pubmed-author:MalmqvistKarinK,
pubmed-author:MelhusHåkanH,
pubmed-author:MichaelssonKarlK,
pubmed-author:NyströmFredrikF,
pubmed-author:OhmanK PeterKP,
pubmed-author:SyvänenAnn-ChristineAC
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
27
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
169-73
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:15049387-Antihypertensive Agents,
pubmed-meshheading:15049387-Atenolol,
pubmed-meshheading:15049387-Biphenyl Compounds,
pubmed-meshheading:15049387-Double-Blind Method,
pubmed-meshheading:15049387-Female,
pubmed-meshheading:15049387-Genotype,
pubmed-meshheading:15049387-Humans,
pubmed-meshheading:15049387-Hypertension,
pubmed-meshheading:15049387-Hypertrophy, Left Ventricular,
pubmed-meshheading:15049387-Linear Models,
pubmed-meshheading:15049387-Male,
pubmed-meshheading:15049387-Polymorphism, Genetic,
pubmed-meshheading:15049387-Sweden,
pubmed-meshheading:15049387-Tetrazoles,
pubmed-meshheading:15049387-Transforming Growth Factor beta,
pubmed-meshheading:15049387-Treatment Outcome
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
Transforming growth factor beta1 genotype and change in left ventricular mass during antihypertensive treatment--results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA).
|
|
pubmed:affiliation |
Department of Medical Sciences, Uppsala University, Uppsala, Sweden. par.hallberg@medsci.uu.se
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|
